TNF Pharmaceuticals Inc.
TNFA
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.18M
Close$
$6.67
28.3% upside
Current Fair Value
28.3% upsideUndervalued by 28.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.18 Million |
|---|---|
| Enterprise Value | $8.98 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1115 |
| Beta | 2.28 |
| Outstanding Shares | 156,989 |
Return
| Return on Equity | -59.60% |
|---|---|
| Return on Assets | -40.32% |
| Return on Invested Capital | -71.40% |
Valuation & Multiples
| P/E Ratio | -3 |
|---|---|
| PEG | 3.69 |
| Price to Sales | - |
| Price to Book Ratio | 0.07 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.08 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 13, 2025
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.06%▼ 9.88% |
|---|---|
| Total Invested | $3▼ 100.00% |
| Investors Holding | 1▼ 28.00% |
ESG Score
No data
About TNF Pharmaceuticals Inc.
CEO: Howard Yeaton mymd is a clinical stage biotech pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. mymd-1 is a drug platform based on a clinical stage small molecule that regulates the ...